Anastrozole is an oral nonsteroidal aromatase inhibitor used to treat advanced breast cancer in postmenopausal women by preventing the conversion of adrenal androgens into estrogen.1 This contrasts with the better-known antiestrogen drug tamoxifen, which blocks estrogen from binding to its receptor in breast tissue. Reported ophthalmologic adverse effects of anastrozole include retinal hemorrhages, bilateral optic disc swelling, vitreoretinal traction, dry eye, and possibly uveitis and macular edema.1 This case report describes a patient receiving anastrozole therapy who was found to have crystalline retinopathy.
Wieder MS, Harooni M, Rusu I. Association of Crystalline Retinopathy With Anastrozole. JAMA Ophthalmol. 2019;137(5):581–582. doi:10.1001/jamaophthalmol.2019.0064
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.